Table 1 Patient characteristics at baseline
From: Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
Characteristic | US | Japan |
|---|---|---|
N = 15,488 | N = 6020 | |
aExcluded from the denominator for non-missing data | ||
Age at index, years | ||
Mean (SD) | 70.2 (12.4) | 76.8 (11.4) |
Median (IQR) | 71 (62–80) | 78 (71–85) |
Male, n (%) | 8176 (52.8) | 3810 (63.3) |
History of HK, n (%) | 6064 (39.2) | 961 (16.0) |
HK severity at index, n (%) | ||
> 5.0–5.49 | 4940 (48.6) | 207 (32.8) |
5.5–5.99 | 3414 (33.6) | 268 (42.5) |
≥ 6 | 1805 (17.8) | 156 (24.7) |
Missinga | 5329 (34.4) | 5389 (89.5) |
Diabetes, n (%) | 10,236 (66.1) | 2550 (42.4) |
CKD stage by diagnosis code or by eGFR, n (%) | ||
3 or 4 | 11,873 (76.7) | 1427 (23.7) |
3 | 8931 (57.7) | 534 (8.9) |
4 | 2942 (19.0) | 893 (14.8) |
HF, n (%) | 9086 (58.7) | 5348 (88.8) |
RAASi, n (%) | ||
ACEi | 8886 (57.4) | 1281 (21.3) |
ARB | 4786 (30.9) | 4037 (67.1) |
ARNi | 758 (4.9) | 38 (0.6) |
MRA | 3803 (24.6) | 2168 (36.0) |